555 research outputs found
MASLD is associated with an increased long-term risk of atrial fibrillation: an updated systematic review and meta-analysis
No full textBackground: studies have reported an association between metabolic dysfunction-associated steatotic liver disease (MASLD) and an increased risk of developing atrial fibrillation (AF). However, the magnitude of the risk and whether this risk varies with the severity of MASLD remains uncertain.Methods: in this systematic review and meta-analysis, we searched three large electronic databases using predefined keywords to identify cohort studies (published up to 30 September 2024) in which MASLD was diagnosed by liver biopsy, imaging methods, International Classification of Diseases (ICD) codes, or blood-based scores. The primary outcome was the occurrence of AF based on ICD codes, medical records, or electrocardiograms. Meta-analysis was performed using random-effects modelling.Results: we identified 16 retrospective cohort studies with aggregate data on ~19.5 million individuals followed for a median of 7.2 years. MASLD was significantly associated with an increased risk of developing incident AF (random-effects hazard ratio 1.20, 95% CI 1.10–1.32; I2 = 92%). This risk did not appear to further increase with the severity of liver fibrosis (n = 3 studies; random-effects hazard ratio 1.22, 95% CI 1.18–1.26; I2 = 10%). The risk of AF remained significant even after adjusting for age, sex, body mass index, hypertension, Type 2 diabetes or other cardiometabolic risk factors. Sensitivity analyses did not modify these findings. The funnel plot and Egger's test showed no significant publication bias.Conclusions: this updated and comprehensive meta-analysis provides evidence that MASLD is significantly associated with an increased long-term risk of developing incident AF. Further research is required to better decipher the link between MASLD and increased AF incidence
Coresponding Author: Nikos Polyzos, Associate Professor of Health Service Management, Former Secretary General of Ministry of Health
No full textAbstract Purpose: The purpose of this study was to access the performance of 117 Greek National Health System (NHS) hospitals for the year 2011, to compare the findings with the results from similar studies of the previous years (2009 and 2010) and to investigate the changes during the last three years of financial crisis. Method: An input-oriented Data Envelopment Analysis was used to measure three indicators, technical, pure technical and scale efficiency indicators. Data was collected from the reports of the web-based facility (ESY.net) which was developed by the General Secretary of Ministry of Health and Social Solidarity. The input variables were the number of physicians, the number of nurses and other personnel, the number of beds and expenditures of every hospital. The output variables were the number of inpatient and outpatient visits. Hospitals were categorized into three size groups. Results: Between the years 2009-2011, all hospitals, especially middle-sized hospitals showed performance improvement on all three indicators. Specific problems were noticed mainly in large-sized hospitals. The technical efficiency of Large-sized hospitals was estimated at 80%, of Middle-sized hospitals at 82% and of Small hospitals-Health Care Centres at 89%. Pure technical and scale efficiency varied between satisfactory levels throughout the study period. Conclusion: Comparing the 2009-2011 data, an improvement of technical efficiency in NHS hospitals has been achieved up to 100%, mainly in the middle-sized hospitals. Specifically, an increase of best practice hospitals has been noted, especially in the middle and small-sized hospitals, when certain units were added the technical efficiency reached over 80%. The consequences of the spending-cuts and the constant reforms appear to have a positive effect on hospitals' efficiency. Hippokratia 2012, 16, 4: 350-35
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
No full textAthanasios D Anastasilakis,1 Konstantinos A Toulis,1 Stergios A Polyzos,2 Chrysostomos D Anastasilakis,3 Polyzois Makras41Department of Endocrinology, 424 General Military Hospital, 2Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, 3Department of Pharmacology, 424 General Military Hospital, Thessaloniki; 4Department of Endocrinology and Diabetes, 251 Hellenic Air Force and VA General Hospital, Athens, GreeceAbstract: Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), a member of the tumor necrosis factor receptor superfamily essential for osteoclastogenesis. Denosumab treatment is associated with a rapid, sustained, and reversible reduction in bone turnover markers, a continuous marked increase in bone mineral density at all sites, and a marked decrease in the risk of vertebral, hip, and nonvertebral fractures in women with postmenopausal osteoporosis. Therefore, it could be considered as an effective alternative to previous bisphosphonate treatment as well as first-line treatment of severe osteoporosis. Cost-effectiveness studies support this suggestion. In addition, denosumab seems to be the safest treatment option in patients with impaired renal function. Denosumab is characterized by reversibility of its effect after treatment discontinuation, in contrast with bisphosphonates. Large-scale clinical trials, including the extension of FREEDOM trial for up to 5 years, are reassuring for its safety. However, given its brief post-market period, vigilance regarding adverse events related to putative RANKL inhibition in tissues other than bone, as well as those related to bone turnover oversuppression, is advised.Keywords: adverse event, denosumab, efficacy, fracture, osteoporosis, safet
A MLPG4 (LBIE) Formulation in Elastostatics
No full textVery recently, Vavourakis, Sellountos and Polyzos (2006) ({CMES: Computer Modeling in Engineering {\&} Sciences, vol. 13, pp. 171--184}) presented a comparison study on the accuracy provided by five different elastostatic Meshless Local Petrov-Galerkin (MLPG) type formulations, which are based on Local Boundary Integral Equation (LBIE) considerations. One of the main conclusions addressed in this paper is that the use of derivatives of the Moving Least Squares (MLS) shape functions decreases the solution accuracy of any MLPG(LBIE) formulation. In the present work a new, free of MLS-derivatives and non-singular MLPG(LBIE) method for solving elastic problems is demonstrated. This is accomplished by treating displacements and stresses as independent variables through the corresponding local integral equations and considering nodal points located only internally and externally and not on the global boundary of the analyzed elastic structure. The MLS approximation scheme for the interpolation of both displacements and stresses is exploited. The essential displacement and traction boundary conditions are easily satisfied via the corresponding displacement and stress local integral equations. Representative numerical examples that demonstrate the achieved accuracy of the proposed MLPG(LBIE) method are provided
Multivariate prediction of subcutaneous glucose concentration in type 1 diabetes patients based on support vector regression.
No full textAbstract
Data-driven techniques have recently drawn significant interest in the predictive modeling of subcutaneous (s.c.) glucose concentration in type 1 diabetes. In this study, the s.c. glucose prediction is treated as a multivariate regression problem, which is addressed using support vector regression (SVR). The proposed method is based on variables concerning: (i) the s.c. glucose profile, (ii) the plasma insulin concentration, (iii) the appearance of meal-derived glucose in the systemic circulation, and (iv) the energy expenditure during physical activities. Six cases corresponding to different combinations of the aforementioned variables are used to investigate the influence of the input on the daily glucose prediction. The proposed method is evaluated using a dataset of 27 patients in free-living conditions. 10-fold cross validation is applied to each dataset individually to both optimize and test the SVR model. In the case where all the input variables are considered, the average prediction errors are 5.21, 6.03, 7.14 and 7.62 mg/dl for 15, 30, 60 and 120 min prediction horizons, respectively. The results clearly indicate that the availability of multivariable data and their effective combination can significantly increase the accuracy of both short-term and long-term predictions
Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis
No full textObjective: epidemiological studies have reported an association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease (MASLD). However, the magnitude of the risk and whether this risk changes with the severity of MASLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between primary hypothyroidism and the risk of MASLD. Design: we systematically searched PubMed, Scopus and Web of Science from database inception to 31 January 2024, using predefined keywords to identify observational studies in which MASLD was diagnosed by liver biopsy, imaging or International Classification of Diseases codes. A meta-analysis was performed using random-effects modelling. Results: we identified 24 cross-sectional and 4 longitudinal studies with aggregate data on ∼76.5 million individuals. Primary hypothyroidism (defined as levothyroxine replacement treatment, subclinical hypothyroidism or overt hypothyroidism) was associated with an increased risk of prevalent MASLD (n=24 studies; random-effects OR 1.43, 95% CI 1.23 to 1.66; I 2=89%). Hypothyroidism was also associated with a substantially higher risk of metabolic dysfunction-associated steatohepatitis or advanced fibrosis (n=5 studies; random-effects OR 2.84, 95% CI 2.07 to 3.90; I 2=0%). Meta-analysis of data from four longitudinal studies showed that there was a marginally non-significant association between hypothyroidism and risk of developing MASLD over a median 4.5-year follow-up (random-effects HR 1.39, 95% CI 0.98 to 1.97; I 2=85%). Sensitivity analyses did not modify these findings. The funnel plot did not reveal any significant publication bias. Conclusion: this large and updated meta-analysis provides evidence that primary hypothyroidism is significantly associated with both an increased presence of and histological severity of MASLD.</p
- …
